Making the change to MES – The transition to MES Technology
Posted on April 6, 2017 by
Evolving regulatory landscapes and pressures are leading to an increasing number of pharmaceutical companies making the move to manufacturing execution system (MES) technology. The ability of MES systems to improve efficiency and make better use of available resource means they can not only optimise production activities on a single plant, but on multiple plants in multiple locations.
However, making the transition to MES is not without its complexities and there are important factors to consider to ensure you make the most of your investment.
The role of support models
It is important to ensure that any new technologies that are implemented can be updated and supported throughout their entire lifecycle. Ensuring the right support model is in place will help to guarantee the best long term use of the system and ensure the benefits of MES are realised within your organisation.
Most operational challenges occur when systems are not adequately supported. Manufacturing systems should be supported in the same process driven way as IT operations, on an ongoing basis.
The advent of managed services
With the above in mind, outsourcing resource to an external managed services provider can go a long way to ensure the continued running, and ultimately the success, of the MES.
This type of service can support multiple sites, in multiple geographies, giving your team a broader knowledge of the MES across all your sites, allowing for a certain level of standardisation and the ability to implement and improve corporate policy.
Read the full article here: http://www.epmmagazine.com/news/make-that-change/.